2024
Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma
Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Adjuvant Everolimus in Non–Clear Cell Renal Cell Carcinoma. JAMA Network Open 2024, 7: e2425288. PMID: 39106067, DOI: 10.1001/jamanetworkopen.2024.25288.Peer-Reviewed Original ResearchConceptsChromophobe renal cell carcinomaRecurrence-free survivalPapillary renal cell carcinomaRenal cell carcinomaNon-clear cell renal cell carcinomaResected renal cell carcinomaCell renal cell carcinomaOverall survivalWeeks of treatmentCell carcinomaAdverse eventsClinical trialsHazard ratioPhase 3 randomized clinical trialWeeks of everolimusHigher adverse eventsRate of adverse eventsIntermediate-high riskIntervention groupVery-high-riskCox regression modelsPotential treatment benefitsClinical trial dataTreatment-naivePartial nephrectomyBone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer
Gebrael G, Jo Y, Swami U, Plets M, Chehade C, Narang A, Gupta S, Myint Z, Sayegh N, Tangen C, Hussain M, Dorff T, Lara P, Lerner S, Thompson I, Agarwal N. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2419966. PMID: 38980676, PMCID: PMC11234233, DOI: 10.1001/jamanetworkopen.2024.19966.Peer-Reviewed Original ResearchConceptsProgression-free survivalAndrogen deprivation therapyProstate-specific antigenHormone-sensitive prostate cancerBone painOverall survivalPost hoc secondary analysisProstate cancerSurvival outcomesPain statusAssociated with shorter progression-free survivalClinical trialsPresence of bone painProstate-specific antigen levelAssociated with worse overall survivalCastration-resistant prostate cancerShorter progression-free survivalIntention-to-treat populationSecondary analysisZubrod performance statusHigh-volume diseaseCompare survival outcomesCox proportional hazards regression modelsSecondary end pointsProportional hazards regression models
2023
Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses
DiNardo A, Arditi M, Kamat A, Koster K, Carrero S, Nishiguchi T, Lebedev M, Benjamin A, Avalos P, Lozano M, Moule M, McCune B, Herron B, Ladki M, Sheikh D, Spears M, Herrejon I, Dodge C, Kumar S, Hutchison R, Ofili T, Opperman L, Bernard J, Lerner S, Udeani G, Neal G, Netea M, Cirillo J. Bacillus Calmette-Guérin vaccination as defense against SARS-CoV-2 (BADAS): a randomized controlled trial to protect healthcare workers in the USA by enhanced trained immune responses. Trials 2023, 24: 636. PMID: 37794431, PMCID: PMC10548680, DOI: 10.1186/s13063-023-07662-w.Peer-Reviewed Original ResearchConceptsBacillus Calmette-GuerinBacillus Calmette-Guerin vaccineSARS-CoV-2 infectionRandomized controlled trialsSARS-CoV-2BCG vaccinationClinical course of SARS-CoV-2 infectionCourse of SARS-CoV-2 infectionTreatment groupsAdministration of BCG vaccineKaplan-Meier curvesCox proportional hazards modelsEffect of BCG vaccinationInfection in vitroInfection of healthcare workersEvidence of SARS-CoV-2 infectionHealthcare workersMulti-center randomized controlled trialProportional hazards modelImmunological markersIntradermal administrationHazard ratioNon-specific effectsImmune responseHigh risk